linn. Seed extract as antidiabetic agent: and anti-glucolipotoxicity efficacy in Type-II diabetes mellitus.

BACKGROUND

Diabetes, especially type-II, prevailed despite recent medical advances. An edible (GL) seed is sold in Ethiopian traditional market such as 'Merkato' and used in folkloric medicine to treat diabetes. But to date not scientifically proven in this optic. As a result, this study set out to validate this claim.

METHODS

Following seed has been extracted, its antidiabetic efficacy was initially validated before investigation. The activity was probed by employing carbohydrate and lipid metabolizing enzymes inhibition assay. Based on this fact, the antidiabetic efficacy was conducted in normoglycemic, oral glucose-loaded and streptozotocin (150 mg/kg)-nicotinamide (65 mg/kg)-elicited type II diabetic rats.

RESULTS

The extract's LD was found to be greater than 2 g/kg. In vitro tests pill up evidence that seed extract foils carbohydrate and lipid metabolizing enzyme activities (p < 0.001). On the other hand, seed extract significantly abridged blood glucose in normoglycaemic rats markedly (p < 0.05-0.001). The highest dose exhibited the strongest glucose tolerance effect, with a maximum slaying (41.1%) in glucose-loaded rats' plasma glucose (p < 0.001). All doses of the extract ameliorate blood glucose levels significantly in diabetic rats after 4 weeks of therapy (p < 0.05-0.001). Likewise, all test doses tempered harmful lipides in diabetic rats markedly (p < 0.05-0.001). But HDL (p < 0.01-0.001) and body weight losses (p < 0.05-0.001) were rectified.

CONCLUSION

In consequence, our data unveils the safety and glucolipotoxicity inhibition potential of seed extract, authenticating the traditional standpoint that it might be converted into a viable anti-diabetic lead upon subsequent investigations.